Lead Sponsor

First Affiliated Hospital of Fujian Medical University

Collaborators

Age

All ages

Sex

ALL

Healthy Volunteers

Yes

•Pathological diagnosis of ccRCC;
•Availability of complete clinical, pathological, and follow-up data;
•Sufficient preoperative serum available for collection;
•Well-preserved pathological slides for subsequent immunohistochemical (chip) analysis;
•At least one post-treatment follow-up/efficacy evaluation.

•Therapeutic contraindication cohort: Individuals presenting with severe comorbidities rendering them medically ineligible for therapeutic interventions;
•Oncological multiplicity: Subjects with either (a) antecedent therapeutic regimens targeting non-index malignancies or (b) concurrent diagnosis of untreated active malignancies;
•Biospecimen integrity violation: Cases demonstrating serum hemolysis or compromised specimen integrity;
•Data insufficiency cohort: Patients exhibiting incomplete clinical/pathological records or insufficient longitudinal follow-up data for comprehensive analysis.

Related studies

NCT05665361 · Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc)

NCT06318871 · Renal Carcinoma, Renal Cell Carcinoma, and more

NCT07316465 · Atopic Dermatitis (AD), Autoantibody, and more

NCT05266898 · Papillomavirus Vaccines, Human Immunodeficiency Virus, and more

NCT04890444 · Cushing Syndrome, Aldosteronism, and more

Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study